NEURAXO BIOPHARMACEUTICALS GMB has a total of 12 patent applications. Its first patent ever was published in 1998. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals and biotechnology are ALKERMES CONTROLLED THERAPEUTICS INC, NYCOMED DANMARK APS and BEECHAM PHARM PTE LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | United States | 2 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Masanneck Carmen | 6 |
#2 | Hermanns Susanne | 5 |
#3 | Vereyken Ingrid | 4 |
#4 | Franssen Okke | 4 |
#5 | Mueller Hans Werner | 2 |
#6 | Stichel-Gunkel Christine C | 2 |
#7 | Muller Hans W | 1 |
#8 | Ingrid Vereyken | 1 |
#9 | Carmen Masanneck | 1 |
#10 | Okke Franssen | 1 |
Publication | Filing date | Title |
---|---|---|
WO2008003780A2 | Use of proteins of the sdf-1-family for improvement of axonal plasticity or for axonal regeneration following lesions | |
EP2000134A1 | Use of a substance for the improvement of pns lesions | |
WO2007048846A1 | Use of iron-chelating compounds, cyclic adenosine monophosphate-increasing compounds or combinations thereof for treating axonal lesions in the cns | |
KR20080044845A | Pharmaceutical composition comprising an iron chelator | |
EP0981549A1 | Use of an inhibitor substance for the improvement of neuronal regeneration |